Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The global market is expected to enjoy a valuation of US$ 4.4 Billion by the end of the year 2023, and further expand at a CAGR of 2.72% to reach a valuation of ~US$ 5.8 Billion by the year 2033. According to the recent study by Future Market Insights, anti- psychotic drugs are leading the market with an expected share of about 40.2% in the year 2023, within the global market.
Market Outlook
Data Points | Market Insights |
---|---|
Market Value 2022 | US$ 4.3 Billion |
Market Value 2023 | US$ 4.4 Billion |
Market Value 2033 | US$ 5.8 Billion |
CAGR 2023 to 2033 | 2.72% |
Market Share of Top 5 Countries | 73.6% |
Key Market Players | AbbVie Inc., Glaxo SmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Bristol Myers Squibb, Gedeon Richter Plc., H. Lundbeck A/S, Pfizer Inc., Novartis AG, Otsuka Holdings Co. Ltd, Validus Pharmaceuticals LLC |
Changing perspective about the importance of mental health treatments is anticipated to raise the sale of over the counter meds for bipolar disorder. According to the Global Burden of Disease report 2017, the prevalence of bipolar disorder ranges from 0.3% to 1.2% among different regions. In recent years, there has been growing awareness about the disorder, shifting the perspective for it as a mental ailment creating a surge in the sale of natural bipolar medication.
With the changing perspective about mental health, the demand for natural bipolar meds or drugs is anticipated to grow by the patients suffering from such disease. A similar category of drugs, commonly known as bipolar depression treatment medication, is increasingly available in all parts of the world.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for bipolar disorder drugs and treatment was approximately 20.3% of the overall ~US$ 21.2 Billion of the global psychotropic drugs market in 2022.
The sale of bipolar disorder drugs and treatment expanded at a CAGR of 2.10% from 2017 to 2022.
The market for bipolar disorder drugs and treatment was mildly hit by the COVID-19 pandemic restrictions. As there were widespread positive cases of patients infected by the novel coronavirus, most of the resources and professionals of the healthcare sector were diverted towards the management of the COVID-19 menace.
Particularly the demand for medication for bipolar from the hospital and healthcare institutions dropped significantly. Surprisingly enough, the number of patients diagnosed with bipolar disorders increased significantly during the worldwide shutdown. This fact is hypothesized from the information of the increase in the volume of over the counter medicine for bipolar available during the pandemic times. However, the market growth for prescribed drugs continued through the increase in online availability of bipolar meds on e-commerce sites.
As the healthcare sector was kept as the most prioritized business sector, the drugs market recovered from the jolt of the pandemic within a few days. There were also some remarkable developments in the field of herbal medicine for bipolar disorder that has emerged as a successful niche for the bipolar disorder drugs and treatment market.
Thus, owing to the aforementioned factors, the global bipolar disorder drugs and treatment market is expected to grow at a CAGR of 2.72% during the forecast period from 2023 to 2033.
Market Statistics | Details |
---|---|
Jan to Jun (H1), 2021 (A) | 1.91% |
Jul to Dec (H2), 2021 (A) | 2.43% |
Jan to Jun (H1),2022 Projected (P) | 1.73% |
Jan to Jun (H1),2022 Outlook (O) | 1.86% |
Jul to Dec (H2), 2022 Outlook (O) | 2.68% |
Jul to Dec (H2), 2022 Projected (P) | 2.43% |
Jan to Jun (H1), 2023 Projected (P) | 2.12% |
BPS Change : H1,2022 (O) - H1,2022 (P) | 12↑ |
BPS Change : H1,2022 (O) - H1,2021 (A) | (-) 6↓ |
BPS Change: H2, 2022 (O) - H2, 2022 (P) | 25↑ |
BPS Change: H2, 2022 (O) - H2, 2021 (A) | 25↑ |
Bipolar disorders have been recognized as the 6th largest contributor in the total disabled person in the world, by World Health Organizations or WHO. To mitigate the serious consequences, modern medical science has developed therapeutic drugs for its treatment that is available as over the counter meds in the drug stores.
Previously the consciousness and awareness about the remedial measures for any type of mental disorder were below the level, resulting in less demand for good medicine for bipolar disorder produced by the pharmaceutical companies. However, in recent days with the growth in digital media, the acceptance of methods for treatment of bipolar is reflected in the huge growth in sales of over the counter meds for bipolar cases.
There is also some old age natural medication for bipolar disorder that is being actively researched and developed by pharmaceutical companies to augment their customer base. Many market players have succeeded in creating brand values by supplying mood stabilizers online to customers.
The lithium (Li) element used in the production of anti-mania drugs can cause anorexia if taken by an overdose. Also, the prolonged use of lithium can damage the effects of vasopressin hormone that can result in diabetes insipid, as cited by many reports. This tact can hinder the wider adaptability of bipolar over the counter meds for disorder treatment as well.
As the typical age group for the emergence of any symptom of bipolar disorder is around 20 to 25 years, so it often gets neglected by the parents. This delays the tremendous procedure for bipolar disorders and reduces the effectiveness of natural bipolar meds, and hampers the value of the drug in the market. Over the years, a lot of generic medicines have been coming into the market competing with the well-established market chains of OTC mood stabilizer medications.
Addiction of the body to such types of drugs is another major concern for the use of bipolar treatment drugs by the patients. There is also very less number of anticonvulsant drugs approved for use as bipolar disorder medication over the counter that can hamper the rapid growth of the global market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Country | USA |
---|---|
2023 | 52.90% |
2033 | 54.20% |
BPS | 129 |
Country | Germany |
---|---|
2023 | 6.90% |
2033 | 6.90% |
BPS | (-) 2 |
Country | United kingdom |
---|---|
2023 | 5.30% |
2033 | 5.40% |
BPS | 9 |
Country | Brazil |
---|---|
2023 | 4.40% |
2033 | 4.40% |
BPS | 7 |
Country | France |
---|---|
2023 | 4.10% |
2033 | 4.10% |
BPS | 5 |
The USA is set to obtain a share of around 52.90% in the global market, in 2023.
National Institute of Mental Health (NIMH) provides data for the number of people in USA developing bipolar disorder symptoms at approximately 10 million. By the support of government initiatives and dissemination of knowledge about the mental condition of such patients, there has been an encouraging environment for their treatment through proper medication for bipolar disorder.
The increase in disruption of daily lifestyle like insufficient sleep, wrong food habits or substance abuse and higher stress level in the youngster is the reason for the increasing sale of mood stabilizer medications over the counter, particularly in the USA.
Germany is set to hold a market share of nearly 6.90% in the global bipolar disorder drugs and treatment market in 2023.
Strong policies to regulate the sale of over the counter medication for bipolar disorder is expected to enhance the growth of bipolar disorder drugs and the treatment market in this region.
China is set to expand at a CAGR of 2.50% in the global market, over the forecast period.
A rising frequency of mental diseases, greater awareness of bipolar disorders, and higher investments by major firms are all contributing to China's expected position as the market with the highest growth. A high patient population and rising public awareness of mental health issues have driven the market in the nation.
Anti-psychotic drugs segment leads the market and is expected to hold a share of around 40.23% globally, in 2023.
Since they were first introduced into psychiatric therapy, antipsychotic drugs have been used to treat acute episodes of bipolar disease and prevent relapses. With the release of second-generation antipsychotic drugs, there has been a resurgence in interest in the ability of this class of drugs to treat manic-depression, which has increased the market share.
Bipolar I disorder segment is set to hold a global market share of around 38.46% in 2023.
Manic episodes that continue at least seven days or manic symptoms severe enough to require emergency hospitalization are signs of bipolar I disorder. According to estimates from the National Institute of Mental Health (2020), 4.4% of American adults may experience bipolar illness at some point in their lifetime, which has sparked interest in the market segment globally.
Hospital pharmacies is set to hold nearly half of the global a market share in 2023.
Growing rates of hospitalization as well as rising awareness on mental health globally has propelled the growth of this segment. Institutionalized patients have access to prescription drugs required for alleviation of disease symptoms, as well as for therapeutic purposes. Moreover, with access to adequate distribution networks, the segment is expected to gain traction over the forecast period, owed to greater accessibility of medications.
Bipolar Disorder Drugs and Treatment Market:
Attributes | Bipolar Disorder Drugs and Treatment Market |
---|---|
CAGR (2023 to 2033) | 2.72% |
Market Value (2023) | US$ 4.4 Billion |
Growth Factor | The rise of the market in low- and middle-income nations is being facilitated by government activities aimed at increasing awareness and sensitising society about bipolar disorder patients in order to destigmatize the condition. The rising cost of government healthcare will also fuel the market's expansion. |
Key Market Trend | Medical research and developments have widened the field of medicine to cover additional conditions and their symptoms. More diagnoses are made as a result of medicine's broadening focus to address all facets of the condition, which drives up the market for bipolar disorders worldwide. |
Depression Treatment Market:
Attributes | Depression Treatment Market |
---|---|
CAGR (2023 to 2033) | 5.2% |
Market Value (2023) | US$ 10.6 Billion |
Growth Factor | Changing demography, environmental conditions, and increased mental stress are all factors leading to the rise in mental health issues. As a result, the market for treating depression is expanding. |
Key Trend | Governments are attempting to improve funding for mental health services as well as treatment for mental illness and depression disorders. Among the factors driving the market are the need for high-quality therapies, affordable healthcare policies, government financing, and healthcare facility interventions for mental health issues treatment. |
Anxiety Disorders and Depression Treatment Market:
Attributes | Anxiety Disorders and Depression Treatment Market |
---|---|
CAGR (2023 to 2033) | 3.4% |
Market Value (2023) | US$ 11.6 Billion |
Growth Factor | It is projected that efforts made by pharmaceutical companies, NGOs, mental health organisations, and government initiatives to increase public awareness will speed up market growth in the ensuing years. In order to ensure prompt care of depression and anxiety the government's goal of lowering the financial costs of these disorders is anticipated to boost product demand. |
Key Trend | Through research and development, patient treatment for illnesses related to mental health is being improved globally. Due to inventive research that led to combination therapies using brand-new or existing drug molecules, there are currently more candidates for the management of depression and anxiety disorders in the pipeline, which will increase market growth internationally. |
The main strategies adopted by the market players include the development of new drugs for bipolar disorder over the counter medication by investing in research and development (R&D) activities. Acquiring approvals for such over the counter medications is the most important step in gaining recognition for the newly developed medicines.
Expanding business activities by acquisition and merger of the locally established manufacturers supplying mood stabilizer medications over the counter in any area.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the bipolar disorder drugs and treatment space, which are available in the full report.
Attribute | Details |
---|---|
Forecast Period | 2023 to 2033 |
Historical Data Available for | 2017 to 2022 |
Market Analysis | US$ Mn for Value |
Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United kingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa |
Key Market Segments Covered | Drug Class, Bipolar Disorder, Distribution Channel, and Region |
Key Companies Profiled |
|
Pricing | Available upon Request |
In 2023, the market is expected to attain US$ 4.4 billion.
The sales are to spur to US$ 5.8 billion in 2033.
Through 2033, the market is set to evolve at a CAGR of 2.72%.
From 2018 to 2022, the global market advanced at a CAGR of 2.1%.
In 2023, the United States is expected to possess a global market share of 52.90%.
In 2023, Germany is anticipated to have a 6.90% market share globally.
1. Executive Summary | Bipolar Disorder Drugs and Treatment Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Market Innovation / Development Trends 4. Key Success Factors 4.1. Disease Epidemiology, by Region 4.2. Product Adoption / Usage Analysis 4.3. Pipeline Assessment 4.4. Regulatory Landscape 4.5. Reimbursement Scenario 4.6. PESTEL Analysis 4.7. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Outlook 5.1.3. Global Psychotropic Drugs Market Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Rising Awareness on Mental Health Care 5.2.2. Increasing Government Support for Psychiatric Disorders 5.2.3. High Prevalence of Neurological and Neuropsychiatric Disorders 5.2.4. Regulatory Scenario 5.2.5. Reimbursement Considerations 5.2.6. Cost of Treatment Regime 5.2.7. Concerns with Addition from Treatment Drugs 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. By Drug Class 6.1.2. By Bipolar Disorder 6.1.3. By Distribution Channel 6.1.4. By Country 6.2. 2022 Market Scenario 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 7.2. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2017 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 8.3.1. Mood Stabilizer 8.3.2. Anticonvulsants 8.3.3. Anti-Psychotic Drugs 8.3.4. Anti-Depressant Drugs 8.3.5. Anti-Anxiety Drugs 8.4. Market Attractiveness Analysis By Drug Class 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Bipolar Disorder 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis, By Bipolar Disorder, 2017 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Bipolar Disorder, 2023 to 2033 9.3.1. Bipolar I Disorder 9.3.2. Bipolar Ii Disorder 9.3.3. Cyclothymic Disorder 9.4. Market Attractiveness Analysis By Bipolar Disorder 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 10.3.1. Hospital Pharmacies 10.3.2. Retail Pharmacies 10.3.3. Online Pharmacies 10.4. Market Attractiveness Analysis By Distribution Channel 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 12.3.1. By Country 12.3.1.1. USA 12.3.1.2. Canada 12.3.2. By Drug Class 12.3.3. By Bipolar Disorder 12.3.4. By Distribution Channel 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Drug Class 12.4.3. By Bipolar Disorder 12.4.4. By Distribution Channel 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country Level Analysis & Forecast 12.8.1. USA Market Analysis 12.8.1.1. .Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Drug Class 12.8.1.2.2. By Bipolar Disorder 12.8.1.2.3. By Distribution Channel 12.8.2. Canada Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Drug Class 12.8.2.2.2. By Bipolar Disorder 12.8.2.2.3. By Distribution Channel 13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. Mexico 13.3.1.2. Brazil 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Drug Class 13.3.3. By Bipolar Disorder 13.3.4. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug Class 13.4.3. By Bipolar Disorder 13.4.4. By Distribution Channel 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. Mexico Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Drug Class 13.8.1.2.2. By Bipolar Disorder 13.8.1.2.3. By Distribution Channel 13.8.2. Brazil Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Drug Class 13.8.2.2.2. By Bipolar Disorder 13.8.2.2.3. By Distribution Channel 13.8.3. Argentina Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Drug Class 13.8.3.2.2. By Bipolar Disorder 13.8.3.2.3. By Distribution Channel 14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. United kingdom 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Drug Class 14.3.3. By Bipolar Disorder 14.3.4. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Drug Class 14.4.3. By Bipolar Disorder 14.4.4. By Distribution Channel 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. Germany Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Drug Class 14.8.1.2.2. By Bipolar Disorder 14.8.1.2.3. By Distribution Channel 14.8.2. Italy Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. B By Drug Class 14.8.2.2.2. By Bipolar Disorder 14.8.2.2.3. By Distribution Channel 14.8.3. France Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Drug Class 14.8.3.2.2. By Bipolar Disorder 14.8.3.2.3. By Distribution Channel 14.8.4. United kingdom Market Analysis 14.8.4.1. Introduction 14.8.4.2. Market Analysis and Forecast by Market Taxonomy 14.8.4.2.1. By Drug Class 14.8.4.2.2. By Bipolar Disorder 14.8.4.2.3. By Distribution Channel 14.8.5. Spain Market Analysis 14.8.5.1. Introduction 14.8.5.2. Market Analysis and Forecast by Market Taxonomy 14.8.5.2.1. By Drug Class 14.8.5.2.2. By Bipolar Disorder 14.8.5.2.3. By Distribution Channel 14.8.6. BENELUX Market Analysis 14.8.6.1. Introduction 14.8.6.2. Market Analysis and Forecast by Market Taxonomy 14.8.6.2.1. By Drug Class 14.8.6.2.2. By Bipolar Disorder 14.8.6.2.3. By Distribution Channel 14.8.7. Russia Market Analysis 14.8.7.1. Introduction 14.8.7.2. Market Analysis and Forecast by Market Taxonomy 14.8.7.2.1. By Drug Class 14.8.7.2.2. By Bipolar Disorder 14.8.7.2.3. By Distribution Channel 15. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Drug Class 15.3.3. By Bipolar Disorder 15.3.4. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug Class 15.4.3. By Bipolar Disorder 15.4.4. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. China Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Drug Class 15.8.1.2.2. By Bipolar Disorder 15.8.1.2.3. By Distribution Channel 15.8.2. Japan Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Drug Class 15.8.2.2.2. By Bipolar Disorder 15.8.2.2.3. By Distribution Channel 15.8.3. South Korea Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Drug Class 15.8.3.2.2. By Bipolar Disorder 15.8.3.2.3. By Distribution Channel 16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Indonesia 16.3.1.3. Malaysia 16.3.1.4. Thailand 16.3.1.5. Rest of South Asia 16.3.2. By Drug Class 16.3.3. By Bipolar Disorder 16.3.4. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug Class 16.4.3. By Bipolar Disorder 16.4.4. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. India Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Drug Class 16.8.1.2.2. By Bipolar Disorder 16.8.1.2.3. By Distribution Channel 16.8.2. Indonesia Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Drug Class 16.8.2.2.2. By Bipolar Disorder 16.8.2.2.3. By Distribution Channel 16.8.3. Malaysia Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Drug Class 16.8.3.2.2. By Bipolar Disorder 16.8.3.2.3. By Distribution Channel 16.8.4. Thailand Market Analysis 16.8.4.1. Introduction 16.8.4.2. Market Analysis and Forecast by Market Taxonomy 16.8.4.2.1. By Drug Class 16.8.4.2.2. By Bipolar Disorder 16.8.4.2.3. By Distribution Channel 17. Oceania Market 2017-2022 and Forecast 2023-2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Drug Class 17.3.3. By Bipolar Disorder 17.3.4. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug Class 17.4.3. By Bipolar Disorder 17.4.4. By Distribution Channel 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. Australia Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Drug Class 17.8.1.2.2. By Bipolar Disorder 17.8.1.2.3. By Distribution Channel 17.8.2. New Zealand Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Drug Class 17.8.2.2.2. By Bipolar Disorder 17.8.2.2.3. By Distribution Channel 18. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Türkiye 18.3.1.3. North Africa 18.3.1.4. South Africa 18.3.1.5. Rest of Middle East and Africa 18.3.2. By Drug Class 18.3.3. By Bipolar Disorder 18.3.4. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Drug Class 18.4.3. By Bipolar Disorder 18.4.4. By Distribution Channel 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. GCC Countries Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Drug Class 18.8.1.2.2. By Bipolar Disorder 18.8.1.2.3. By Distribution Channel 18.8.2. Türkiye Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Drug Class 18.8.2.2.2. By Bipolar Disorder 18.8.2.2.3. By Distribution Channel 18.8.3. South Africa Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Drug Class 18.8.3.2.2. By Bipolar Disorder 18.8.3.2.3. By Distribution Channel 18.8.4. North Africa Market Analysis 18.8.4.1. Introduction 18.8.4.2. Market Analysis and Forecast by Market Taxonomy 18.8.4.2.1. By Drug Class 18.8.4.2.2. By Bipolar Disorder 18.8.4.2.3. By Distribution Channel 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Share Analysis of Top Players 19.3. Market Presence Analysis 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. AbbVie Inc. 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Sales Footprint 20.3.1.4. Key Financials 20.3.1.5. SWOT Analysis 20.3.1.6. Strategy Overview 20.3.1.6.1. Marketing Strategy 20.3.1.6.2. Product Strategy 20.3.1.6.3. Channel Strategy 20.3.2. Glaxo SmithKline (GSK) 20.3.3. ELI Lilly and Company 20.3.4. Janssen Pharmaceuticals 20.3.5. Astellas Pharma Inc. 20.3.6. Bristol Myers Squibb 20.3.7. Gedeon Richter Plc. 20.3.8. H. Lundbeck A/S 20.3.9. Pfizer Inc. 20.3.10. Novartis AG 20.3.11. Otsuka Holdings Co. Ltd 20.3.12. Validus Pharmaceuticals LLC 21. Assumptions and Acronyms Used 22. Research Methodology
Table 01: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class Table 02: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033by Bipolar Disorder Table 03: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel Table 04: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region Table 05: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country Table 06: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class Table 07: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Bipolar Disorder Table 08: North America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel Table 09: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country Table 10: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class Table 11: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Bipolar Disorder Table 12: Latin America Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel Table 13: Europe Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country Table 14: Europe Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class Table 15: Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033by Bipolar Disorder Table 16: Europe Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel Table 17: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country Table 18: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class Table 19: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Bipolar Disorder Table 20: East Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel Table 21: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country Table 22: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class Table 23: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Bipolar Disorder Table 24: South Asia Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel Table 25: Oceania Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country Table 26: Oceania Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class Table 27: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033by Bipolar Disorder Table 28: Oceania Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel Table 29: Middle East & Africa Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country Table 30: Middle East & Africa Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class Table 31: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033by Bipolar Disorder Table 32: Middle East & Africa Market Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Figure 01: Global Market Value (US$ Million) Analysis, 2017 to 2022 Figure 02: Global Market Forecast & Y-o-Y Growth, 2023 to 2033 Figure 03: Global Market Absolute $ Opportunity (US$ Million) Analysis, 2022 to 2033 Figure 04: Global Market Value Share (%) Analysis 2023 and 2033, by Drug Class Figure 05: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by Drug Class Figure 06: Global Market Attractiveness Analysis 2023 to 2033, by Drug Class Figure 07: Global Market Value Share (%) Analysis 2023 and 2033, by Bipolar Disorder Figure 08: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by Bipolar Disorder Figure 09: Global Market Attractiveness Analysis 2023 to 2033, by Bipolar Disorder Figure 10: Global Market Value Share (%) Analysis 2023 and 2033, by Distribution Channel Figure 11: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by Distribution Channel Figure 12: Global Market Attractiveness Analysis 2023 to 2033, by Distribution Channel Figure 13: Global Market Value Share (%) Analysis 2023 and 2033, by Region Figure 14: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by Region Figure 15: Global Market Attractiveness Analysis 2023 to 2033, by Region Figure 16: North America Market Value (US$ Million) Analysis, 2017 to 2022 Figure 17: North America Market Value (US$ Million) Forecast, 2023-2033 Figure 18: North America Market Value Share, by Drug Class (2023 E) Figure 19: North America Market Value Share, by Bipolar Disorder (2023 E) Figure 20: North America Market Value Share, by Distribution Channel (2023 E) Figure 21: North America Market Value Share, by Country (2023 E) Figure 22: North America Market Attractiveness Analysis by Drug Class, 2023 to 2033 Figure 23: North America Market Attractiveness Analysis by Bipolar Disorder, 2023 to 2033 Figure 24: North America Market Attractiveness Analysis by Distribution Channel, 2023 to 2033 Figure 25: North America Market Attractiveness Analysis by Country, 2023 to 2033 Figure 26: USA Market Value Proportion Analysis, 2022 Figure 27: Global Vs. USA Growth Comparison Figure 28: USA Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 29: USA Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 30: USA Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 31: Canada Market Value Proportion Analysis, 2022 Figure 32: Global Vs. Canada. Growth Comparison Figure 33: Canada Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 34: Canada Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 35: Canada Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 36: Latin America Market Value (US$ Million) Analysis, 2017 to 2022 Figure 37: Latin America Market Value (US$ Million) Forecast, 2023-2033 Figure 38: Latin America Market Value Share, by Drug Class (2023 E) Figure 39: Latin America Market Value Share, by Bipolar Disorder (2023 E) Figure 40: Latin America Market Value Share, by Distribution Channel (2023 E) Figure 41: Latin America Market Value Share, by Country (2023 E) Figure 42: Latin America Market Attractiveness Analysis by Drug Class, 2023 to 2033 Figure 43: Latin America Market Attractiveness Analysis by Bipolar Disorder, 2023 to 2033 Figure 44: Latin America Market Attractiveness Analysis by Distribution Channel, 2023 to 2033 Figure 45: Latin America Market Attractiveness Analysis by Country, 2023 to 2033 Figure 46: Mexico Market Value Proportion Analysis, 2022 Figure 47: Global Vs Mexico Growth Comparison Figure 48: Mexico Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 49: Mexico Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 50: Mexico Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 51: Brazil Market Value Proportion Analysis, 2022 Figure 52: Global Vs. Brazil. Growth Comparison Figure 53: Brazil Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 54: Brazil Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 55: Brazil Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 56: Argentina Market Value Proportion Analysis, 2022 Figure 57: Global Vs Argentina Growth Comparison Figure 58: Argentina Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 59: Argentina Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 60: Argentina Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 61: Europe Market Value (US$ Million) Analysis, 2017 to 2022 Figure 62: Europe Market Value (US$ Million) Forecast, 2023-2033 Figure 63: Europe Market Value Share, by Drug Class (2023 E) Figure 64: Europe Market Value Share, by Bipolar Disorder (2023 E) Figure 65: Europe Market Value Share, by Distribution Channel (2023 E) Figure 66: Europe Market Value Share, by Country (2023 E) Figure 67: Europe Market Attractiveness Analysis by Drug Class, 2023 to 2033 Figure 68: Europe Market Attractiveness Analysis by Bipolar Disorder, 2023 to 2033 Figure 69: Europe Market Attractiveness Analysis by Distribution Channel, 2023 to 2033 Figure 70: Europe Market Attractiveness Analysis by Country, 2023 to 2033 Figure 71: UK Market Value Proportion Analysis, 2022 Figure 72: Global Vs. UK Growth Comparison Figure 73: UK Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 74: UK Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 75: UK Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 76: Germany Market Value Proportion Analysis, 2022 Figure 77: Global Vs. Germany Growth Comparison Figure 78: Germany Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 79: Germany Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 80: Germany Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 81: Italy Market Value Proportion Analysis, 2022 Figure 82: Global Vs. Italy Growth Comparison Figure 83: Italy Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 84: Italy Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 85: Italy Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 86: France Market Value Proportion Analysis, 2022 Figure 87: Global Vs France Growth Comparison Figure 88: France Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 89: France Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 90: France Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 91: Spain Market Value Proportion Analysis, 2022 Figure 92: Global Vs Spain Growth Comparison Figure 93: Spain Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 94: Spain Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 95: Spain Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 96: Russia Market Value Proportion Analysis, 2022 Figure 97: Global Vs Russia Growth Comparison Figure 98: Russia Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 99: Russia Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 100: Russia Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 101: BENELUX Market Value Proportion Analysis, 2022 Figure 102: Global Vs BENELUX Growth Comparison Figure 103: BENELUX Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 104: BENELUX Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 105: BENELUX Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 106: East Asia Market Value (US$ Million) Analysis, 2017 to 2022 Figure 107: East Asia Market Value (US$ Million) Forecast, 2023-2033 Figure 108: East Asia Market Value Share, by Drug Class (2023 E) Figure 109: East Asia Market Value Share, by Bipolar Disorder (2023 E) Figure 110: East Asia Market Value Share, by Distribution Channel (2023 E) Figure 111: East Asia Market Value Share, by Country (2023 E) Figure 112: East Asia Market Attractiveness Analysis by Drug Class, 2023 to 2033 Figure 113: East Asia Market Attractiveness Analysis by Bipolar Disorder, 2023 to 2033 Figure 114: East Asia Market Attractiveness Analysis by Distribution Channel, 2023 to 2033 Figure 115: East Asia Market Attractiveness Analysis by Country, 2023 to 2033 Figure 116: China Market Value Proportion Analysis, 2022 Figure 117: Global Vs. China Growth Comparison Figure 118: China Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 119: China Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 120: China Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 121: Japan Market Value Proportion Analysis, 2022 Figure 122: Global Vs. Japan Growth Comparison Figure 123: Japan Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 124: Japan Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 125: Japan Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 126: South Korea Market Value Proportion Analysis, 2022 Figure 127: Global Vs South Korea Growth Comparison Figure 128: South Korea Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 129: South Korea Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 130: South Korea Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 131: South Asia Market Value (US$ Million) Analysis, 2017 to 2022 Figure 132: South Asia Market Value (US$ Million) Forecast, 2023-2033 Figure 133: South Asia Market Value Share, by Drug Class (2023 E) Figure 134: South Asia Market Value Share, by Bipolar Disorder (2023 E) Figure 135: South Asia Market Value Share, by Distribution Channel (2023 E) Figure 136: South Asia Market Value Share, by Country (2023 E) Figure 137: South Asia Market Attractiveness Analysis by Drug Class, 2023 to 2033 Figure 138: South Asia Market Attractiveness Analysis by Bipolar Disorder, 2023 to 2033 Figure 139: South Asia Market Attractiveness Analysis by Distribution Channel, 2023 to 2033 Figure 140: South Asia Market Attractiveness Analysis by Country, 2023 to 2033 Figure 141: India Market Value Proportion Analysis, 2022 Figure 142: Global Vs. India Growth Comparison Figure 143: India Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 144: India Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 145: India Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 146: Indonesia Market Value Proportion Analysis, 2022 Figure 147: Global Vs. Indonesia Growth Comparison Figure 148: Indonesia Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 149: Indonesia Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 150: Indonesia Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 151: Malaysia Market Value Proportion Analysis, 2022 Figure 152: Global Vs. Malaysia Growth Comparison Figure 153: Malaysia Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 154: Malaysia Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 155: Malaysia Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 156: Thailand Market Value Proportion Analysis, 2022 Figure 157: Global Vs. Thailand Growth Comparison Figure 158: Thailand Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 159: Thailand Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 160: Thailand Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 161: Oceania Market Value (US$ Million) Analysis, 2017 to 2022 Figure 162: Oceania Market Value (US$ Million) Forecast, 2023-2033 Figure 163: Oceania Market Value Share, by Drug Class (2023 E) Figure 164: Oceania Market Value Share, by Bipolar Disorder (2023 E) Figure 165: Oceania Market Value Share, by Distribution Channel (2023 E) Figure 166: Oceania Market Value Share, by Country (2023 E) Figure 167: Oceania Market Attractiveness Analysis by Drug Class, 2023 to 2033 Figure 168: Oceania Market Attractiveness Analysis by Bipolar Disorder, 2023 to 2033 Figure 169: Oceania Market Attractiveness Analysis by Distribution Channel, 2023 to 2033 Figure 170: Oceania Market Attractiveness Analysis by Country, 2023 to 2033 Figure 171: Australia Market Value Proportion Analysis, 2022 Figure 172: Global Vs. Australia Growth Comparison Figure 173: Australia Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 174: Australia Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 175: Australia Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 176: New Zealand Market Value Proportion Analysis, 2022 Figure 177: Global Vs New Zealand Growth Comparison Figure 178: New Zealand Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 179: New Zealand Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 180: New Zealand Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 181: Middle East & Africa Market Value (US$ Million) Analysis, 2017 to 2022 Figure 182: Middle East & Africa Market Value (US$ Million) Forecast, 2023-2033 Figure 183: Middle East & Africa Market Value Share, by Drug Class (2023 E) Figure 184: Middle East & Africa Market Value Share, by Bipolar Disorder (2023 E) Figure 185: Middle East & Africa Market Value Share, by Distribution Channel (2023 E) Figure 186: Middle East & Africa Market Value Share, by Country (2023 E) Figure 187: Middle East & Africa Market Attractiveness Analysis by Drug Class, 2023 to 2033 Figure 188: Middle East & Africa Market Attractiveness Analysis by Bipolar Disorder, 2023 to 2033 Figure 189: Middle East & Africa Market Attractiveness Analysis by Distribution Channel, 2023 to 2033 Figure 190: Middle East & Africa Market Attractiveness Analysis by Country, 2023 to 2033 Figure 191: GCC Countries Market Value Proportion Analysis, 2022 Figure 192: Global Vs GCC Countries Growth Comparison Figure 193: GCC Countries Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 194: GCC Countries Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 195: GCC Countries Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 196: Türkiye Market Value Proportion Analysis, 2022 Figure 197: Global Vs. Türkiye Growth Comparison Figure 198: Türkiye Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 199: Türkiye Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 200: Türkiye Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 201: South Africa Market Value Proportion Analysis, 2022 Figure 202: Global Vs. South Africa Growth Comparison Figure 203: South Africa Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 204: South Africa Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 205: South Africa Market Share Analysis (%) by Distribution Channel, 2022 & 2033 Figure 206: North Africa Market Value Proportion Analysis, 2022 Figure 207: Global Vs North Africa Growth Comparison Figure 208: North Africa Market Share Analysis (%) by Drug Class, 2022 & 2033 Figure 209: North Africa Market Share Analysis (%) by Bipolar Disorder, 2022 & 2033 Figure 210: North Africa Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Recommendations
Explore Healthcare Insights
View Reports